Andrew Stewart Plump, President of R&D and a director at Takeda Pharmaceutical Co Ltd (NYSE:TAK), filed a Form 4 on August 21, 2026, disclosing the sale of 19,651 American Depositary Shares on August 19, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Transaction: Andrew Stewart Plump sold 19,651 American Depositary Shares (ADS) on August 19, 2026, at a price of $18.49 per share.
  • Rule 10b5-1 Plan: The sales were made pursuant to a Rule 10b5-1 plan adopted by Plump on May 15, 2026.
  • Reporting Person's Role: Plump serves as both a Director and President, R&D at Takeda Pharmaceutical Co Ltd.
  • Post-Transaction Indirect Ownership: Following the sale, Plump indirectly holds 261,656 ADS by trust.
  • Post-Transaction Direct Ownership: Plump directly holds 766,569 ADS following the reported transaction.
  • Signing: The form was signed by Samuel Ntonme, by power of attorney, for Andrew S Plump, on August 21, 2026.

Details of Plump's ADS Sale at Takeda Pharmaceutical

According to the filing, Andrew Stewart Plump, who holds the titles of Director and President, R&D at Takeda Pharmaceutical Co Ltd (NYSE:TAK), disposed of 19,651 American Depositary Shares on August 19, 2026, at a price of $18.49 per share. The transaction code reported is "S," indicating a sale. The filing notes that the shares sold were held indirectly.

The filing discloses that "the sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026." Following the transaction, Plump's indirect beneficial ownership through a trust stands at 261,656 ADS, while his direct beneficial ownership is reported at 766,569 ADS. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed on August 21, 2026, and covers the earliest transaction date of August 19, 2026. It was filed as an individual filing by one reporting person. The form was signed by Samuel Ntonme, acting by power of attorney on behalf of Andrew S Plump.

What Was Disclosed

Takeda Pharmaceutical Co Ltd director and R&D President Andrew Stewart Plump disclosed the sale of 19,651 ADS at $18.49 per share on August 19, 2026, under a Rule 10b5-1 plan, leaving him with 261,656 ADS held indirectly by trust and 766,569 ADS held directly.